Overview

Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension

Status:
Active, not recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This clinical trial is a study to evaluate the safety, tolerability, and changes in biomarker and clinical outcome assessments of Losmapimod for patients with Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) with an open-label extension.
Phase:
Phase 2
Details
Lead Sponsor:
Fulcrum Therapeutics